1Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies.Arch Dermatol, 2000,136 : 675-676.
2Bagel J, Garland WT, Breneman D, et al. Administration of (DAB389IL-2) to patients with recalcitrant psoriasis: a double blind, phase II multicenter trial. J Am Acad Dermatol, 1998,38 : 938-944.
3Luis Branco, Philip Brarren, Su-Yau Mao,et al. Selective deletion of antigen-specific,activated T cells by a humanized mab to CD2(MEDI-507) is mediated by NK cells. Transplantation, 1999,68:1588-1596.
4Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med, 2001,345:248-55.
5Abrams J R, Levwohl M G, Guzzo C A, et al. CTLA4Ig -mediated blockade of T cell costimulation in patients with psoriasis vulgaris. J Clin Invest, 1999, 103: 1243-1252.
6Gottlieb A, Abdulghani A, Totoristis M, et al. Results of a single-dose, dose-escalating trial of an anti-B7. 1 monoelonal antibody (IDEC- 114) in patients with psoriasis[abstract]. J Invest Dematol, 2000,114:840.
7Papp K, Bissonnette R, Kmeger J G, et al. The treatment of moderate to severe psoriasis with a new anti-CD 11 a monoclonal antibody. J Am Acad Dermatol,2001,45: 665-674.
8Gottlieb A B, Krueger J G, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of Efalizumab, an anti-CD 11 a antibody. Arch Dermatol, 2002,138 : 591-600.
9Asadullah K, Volk H D, Sterry W. Novel immunotherapies for psoriasis. Trends in Immunology, 2002,23 (1):47-53.
10Asadullah K, Friedrich M, Hanneken S, et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol, 2001,116:721-727.
同被引文献19
1赵辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009,12:744.
2Gottliob AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis[J]. Clin Immumol, 2002, 105:105-116.
3Kimball AB, Gordon KB, Langley RG, et al. Safey and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal anti- body,in the treatment of moderate to severe chronic plaque pso- riasis:results of a randomized, placebo-controlled,phase 2 trial[J]. Arch Dermatol, 2008, 144(2): 200-207.
4Korman BD, Tyler KL, Korman N2. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cau- tionary tale for dermatologists[J]. Arch Dermatol, 2009, 145:(8) 937-942.
5Van de Kerkhnf P, Griffths CE, Christophers E, et al. Alefacept in the treatment of psoriasis in patiats for whom conventional therapies are inadrquete[J]. Dermatology, 2005, 211(3): 256-263.
6Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial[J]. Lancet, 2001, 357(9271): 1842-1847.
7Fortaleza GT, Brito Mde F, Santos JB. Splenic tuberculosis dur- ing psoriasis treatment with infliximab [J]. An Bras Dermatol, 2009, 84(4): 420-424.
8Turner D, Picot J, Cooper K, et al. Adalimumab for the treat- ment of psoriasis[J]. Health Technology Assessment, 2009, 13(2): 49-54.
9Schmitt J, Wozel G. Tageted treatment of psoriasis with adali- mumab: a critical appraisal based on a systematic review of the literature[review] [J]. Biologies: Targets and Therapy, 2009, 13(3): 303-318.
10Blomberg M, Zaehariae C, Gronhoj F. Hyperpigmentation of the face following Adalimumab Treatment [J]. Journal Compilation, Acta Dermato-Venerologica, 2009, 89(5): 546-547.
